Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 22 2014
Print

Pfizer, KineMed Extend Diabetes Pact



Published March 28, 2013
Related Searches: Clinical Trials
KineMed, Inc. has renewed a non-exclusive research collaboration with Pfizer for the advancement of novel approaches to metabolic disease, in particular Type II Diabetes. KineMed will use its proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
 
“We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform,” said Dr. Scott Turner, executive vice president, R&D at KineMed. “We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On